BioArctic Interim Report for the period January - March 2026

STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded...